150
Participants
Start Date
February 17, 2023
Primary Completion Date
July 31, 2031
Study Completion Date
October 31, 2031
Tenapanor
Eligible patients from the parent study will continue tenapanor at the same dose assigned in the parent study. Doses can be titrated to either 50 mg BID or 25 mg BID
Advantage Clinical Trials, The Bronx
SUNY Downstate Medical Center, Brooklyn
Frontier Clinical Research, LLC, Smithfield
Frontier Clinical Research, LLC, Scottdale
Frontier Clinical Research, Kingwood
Atrium Health, Charlotte
Prisma Health Children's Hospital, Greenville
Florida Pharmaceutical Research and Associates, Inc., South Miami
Valencia Medical and Research Center, Miami
Prohealth Research Center, Doral
I.H.S. Health, LLC, Kissimmee
G & L Research, LLC, Foley
OSF Saint Francis Medical Center, Peoria
Boys Town National Research Hospital, Boys Town
AIM Trials, LLC, Plano
Pioneer Research Solutions Inc, Sugar Land
Sun Research Institute, San Antonio
Texas Digestive Specialists, Harlingen
Maspons Pediatric Gastro, El Paso
Advanced Research Center, Inc., Anaheim
Lead Sponsor
Ardelyx
INDUSTRY